ATE Stock Overview
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Antibe Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.29 |
| 52 Week High | CA$1.23 |
| 52 Week Low | CA$0.15 |
| Beta | 0.12 |
| 1 Month Change | -31.40% |
| 3 Month Change | -67.93% |
| 1 Year Change | -45.37% |
| 3 Year Change | -92.99% |
| 5 Year Change | -91.57% |
| Change since IPO | -94.64% |
Recent News & Updates
Recent updates
Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?
Dec 15
We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully
Mar 20Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business
Oct 16Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook
Feb 11We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate
Jan 07
Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)
Jul 31Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021
Jul 29Shareholder Returns
| ATE | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -6.6% | 0.7% |
| 1Y | -45.4% | 41.0% | 4.9% |
Return vs Industry: ATE underperformed the Canadian Pharmaceuticals industry which returned 41% over the past year.
Return vs Market: ATE underperformed the Canadian Market which returned 4.9% over the past year.
Price Volatility
| ATE volatility | |
|---|---|
| ATE Average Weekly Movement | 31.4% |
| Pharmaceuticals Industry Average Movement | 13.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ATE's share price has been volatile over the past 3 months.
Volatility Over Time: ATE's weekly volatility has increased from 17% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 11 | Dan Legault | www.antibethera.com |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company’s pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain.
Antibe Therapeutics Inc. Fundamentals Summary
| ATE fundamental statistics | |
|---|---|
| Market cap | CA$15.64m |
| Earnings (TTM) | -CA$18.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs ATE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATE income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$18.24m |
| Earnings | -CA$18.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATE perform over the long term?
See historical performance and comparison